Humacyte (HUMA) Q2 2026 Earnings Call Transcript

Humacyte’s Aug. 12, 2026 earnings call highlighted clinical and commercial milestones for Symvess. For Q2 2026, product revenue was $0.4 million versus $0.1 million a year earlier, driven by the ongoing launch of Symvess. In the V012 Phase III program, women receiving acellular tissue engineered vessels (ATEV) achieved 91 additional catheter-free days compared with those receiving AV fistula, meeting the primary endpoint with a p-value of 0.0007. Infection rates were 6 per 100 patient-years for ATEV versus 23 for AV fistula. Humacyte targeted a supplemental BLA filing for dialysis access in Nov. 2026, with a potential dialysis launch at end of Q2 2027 assuming priority review and a PDUFA date in May 2027. Cash totaled $80.3 million as of June 30, 2026.